Skip to main content

Aptorum Group Limited (APM)

NASDAQ: APM · IEX Real-Time Price · USD
1.91
0.04 (2.14%)
At close: Nov 26, 2021 1:00 PM
1.96
0.05 (2.62%)
After-hours:Nov 26, 2021 2:12 PM EST
Market Cap68.05M
Revenue (ttm)911,509
Net Income (ttm)6.31M
Shares Out35.63M
EPS (ttm)-0.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume484,853
Open2.13
Previous Close1.87
Day's Range1.81 - 1.91
52-Week Range2.12 - 4.94
Beta-0.20
AnalystsStrong Buy
Price Target12.67 (+563.2%)
Earnings Daten/a

About APM

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health...

IndustryBiotechnology
IPO DateDec 18, 2018
Employees25
Stock ExchangeNASDAQ
Ticker SymbolAPM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for Aptorum Group stock is "Strong Buy." The 12-month stock price forecast is 12.67, which is an increase of 563.18% from the latest price.

Price Target
$12.67
(563.18% upside)
Analyst Consensus: Strong Buy

News

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceuti...

1 month ago - Business Wire

Aptorum Group Limited Interview to Air on Bloomberg U.S.

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM), a clinical stage biopharmaceutical company focused on novel te...

1 month ago - Business Wire

Aptorum To Start Testing SACT-1 In Neuroblastoma Patients

The FDA has signed off Aptorum Group Limited's (NASDAQ: APM) IND application to initiate clinical trials of SACT-1 for neuroblastoma. The IND-opening trial is a bioavailability/food effect study that wi...

2 months ago - Benzinga

Aptorum Group Limited Has Received IND Clearance From the US FDA to Initiate Clinical Trials for Repurposed Small Mol...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceuti...

2 months ago - Business Wire

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2021

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmac...

2 months ago - Business Wire

Aptorum Shares Move Higher After Interim Data From Staphylococcus Aureus Candidate

Aptorum Group Limited (NASDAQ: APM) announces further interim data from its ongoing Phase 1 trial for ALS-4 targeting Staphylococcus aureus.  Specifically, two additional cohorts (Cohort C & D) of the s...

4 months ago - Benzinga

Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococ...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #MRSA--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, ...

4 months ago - Business Wire

Aptorum Group Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM), a clinical-stage biopharmaceutical company focused on the deve...

4 months ago - Business Wire

Aptorum Group CEO Subscribed Shares In The Company

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group”, the “Company”), a clinical-stage biopharmaceutical company foc...

6 months ago - Business Wire

3 Penny Stocks on Reddit Making Big Waves Right Now

Which Reddit penny stocks are investors watching right now? Check these 3 out The post 3 Penny Stocks on Reddit Making Big Waves Right Now appeared first on Penny Stocks to Buy, Picks, News and Informat...

Other symbols:LODETHMO
6 months ago - PennyStocks

Aptorum's Shares Jump After ALS-4 Targeting Staphylococcus Aureus Shows Encouraging Action In Early-Stage Study

Aptorum Group Limited (NASDAQ: APM) has completed two initial cohorts of the single-dose ascending dose (SAD) portion of the Phase 1 trial evaluating ALS-4 small molecule targeting Staphylococcus aureus...

6 months ago - Benzinga

Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus an...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceuti...

6 months ago - Business Wire

Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorum's Novel Preclinical Candidate Targeting Woman'...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceuti...

6 months ago - Business Wire

Aptorum Group Limited Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM), a clinical-stage biopharmaceutical company dedicated to meeting unmet medical needs...

7 months ago - Business Wire

Aptorum Shares Are Trading Higher On Immunomodulators Agreement For Autoimmune, Oncology Indications

Aptorum Group Ltd (NASDAQ: APM) has entered into a material transfer and option agreement with Yale University to evaluate a group of preclinical stage novel immunomodulators. Aptorum also obtained an e...

7 months ago - Benzinga

Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its No...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #autoimmune--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical com...

7 months ago - Business Wire

Aptorum Group Limited Reports 2020 Fiscal Year End Financial Results and Provides Business Update

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #MRSA--Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncol...

7 months ago - Business Wire

Aptorum Group Announces Dosing First Human Subject in a Phase I Clinical Trial of ALS-4, a First-in-Class Small Molec...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #MRSA--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel...

7 months ago - Business Wire

APM Stock: 9 Things to Know About Aptorum as Shares Fly on Staph Infection Drug News

Aptorum (APM) stock is on the rise Wednesday after announcing approval to move forward with a clinical trial of its staph infection drug. The post APM Stock: 9 Things to Know About Aptorum as Shares Fly...

10 months ago - InvestorPlace

Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule ...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel t...

10 months ago - Business Wire

Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Dru...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #CTAsubmission--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused...

11 months ago - Business Wire

Aptorum Group Limited Announces Results of 2020 Annual General Meeting of Shareholders

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the “Company”, “Aptorum Group” or “Aptorum”), a biopharmaceuti...

11 months ago - Business Wire

Is Aptorum Group the Best Buy Among Its Peers?

Aptorum Group has competition in the rapid pathogen identification and detection diagnostics (RPIDD) field. Is APM stock the best bet?

1 year ago - InvestorPlace

Don't Get Swept Up In the Unproven Promise of Aptorum Group

Aptorum Group got a boost when the company jumped into the Covid-19 conversation. APM stock looks like a late entry into crowded field.

1 year ago - InvestorPlace

Why Aptorum's New Singapore Deal Makes It a Worthwhile Buy

APM stock is a risky name, but the company's recent deal with Singapore has potentially given it a huge opportunity in Asia. The post Why Aptorum's New Singapore Deal Makes It a Worthwhile Buy appeared ...

1 year ago - InvestorPlace